Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Antagon
Drug ID BADD_D00144
Description Ganirelix is an injectable competitive gonadotropin-releasing hormone antagonist (GnRH antagonist). It is utilized frequently in assisted reproduction therapy to control the occurrence of ovulation. The drug exerts its effects by inhibiting the action of GnRH in the pituitary gland, leading to fast suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Ganirelix is used in fertility treatment to prevent premature ovulation that could result in the harvesting of eggs that are too immature to be used in procedures such as in vitro fertilization. Ganirelix is marketed by Merck & Co., Inc. as Orgalutran®.
Indications and Usage For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
Marketing Status Prescription
ATC Code H01CC01
DrugBank ID DB06785
KEGG ID D08010
MeSH ID C061018
PubChem ID 16130965
TTD Drug ID D00RJJ
NDC Product Code 35207-0010
Synonyms ganirelix | LHRH, N-acetyl-2-naphthylalanyl(1)-(4-chlorophenylalanyl)(2)-3-pyrdinylalanyl(3)-diethylhomoarginyl(6,8)-alaninamide(10)- | N-Ac-(2-naphthyl)Ala-2-(4-Cl-Phe)-3-(3-pyridinyl-Ala)-6,8-Et2-hArg-10-AlaNH2-LHRH | GnRH, N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)- | LHRH,N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)- | ganirelix acetate | N-acetyl-3-(2-naphthyl)-D-alanyl-p-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N(sup 6)-(N,N'-diethylamidino)-D-lysyl-L-leucyl-N(sup 6)-(N,N'-diethylamidino)-L-lysyl-L-prolyl-D-alaninamide diacetate (salt) | ganirelix diacetate | RS-26306-298 | RS 26306 | RS-26306 | Antagon | orgalutran
Chemical Information
Molecular Formula C84H121ClN18O17
CAS Registry Number 124904-93-4
SMILES CCNC(=NCCCCC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN=C(NCC)NCC)C(=O)N1CCCC1C(=O)NC(C)C(=O)N )NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)C l)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC.CC(=O)O.CC(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Malaise08.01.01.003--
Melanocytic naevus23.10.01.007; 16.26.01.007--Not Available
Meningocele17.02.10.006; 03.10.02.002--Not Available
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Ovarian hyperstimulation syndrome21.11.02.007; 05.05.01.013--Not Available
Pelvic pain21.10.01.001; 20.02.03.007; 07.01.06.012--
Polydactyly03.11.07.010; 15.11.07.010--Not Available
Rash23.03.13.001--Not Available
Swelling08.01.03.015--Not Available
Swelling face23.04.01.018; 10.01.05.018--Not Available
Talipes03.11.07.007; 15.11.07.007--Not Available
Torticollis17.01.03.003; 15.05.04.003--Not Available
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Beckwith-Wiedemann syndrome07.11.04.001; 03.12.01.001--Not Available
Foetal death18.01.02.003; 08.04.01.011--
Ill-defined disorder08.01.03.049--Not Available
The 2th Page    First    Pre   2    Total 2 Pages